With overexpression of BCL-2 in CML-MBP and preclinical data showing synergy of venetoclax and BCR-ABL targeting TKIs in eradication of leukemic stem cells, this potent combination could improve response rates for CML-MPB patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.